| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Bromodeoxyuridine (BrdU; Broxuridine; 5-Bromo-2'-deoxyuridine; BUdR) is a nucleoside analog with potential anticancer activity. It has been used in the detection of proliferating cells and functions as an antimetabolite anticancer agent by competing with thymidine for incorporation into DNA. Early on in the dedifferentiation process, the impact of 5-BrdU on the proliferation of grown Nicotiana glauca pith explants was investigated. Only when administered within the first 72 hours of culture did it turn out to be completely inhibitory; this inhibition could be overcome by simultaneously adding either thymidine or deoxyeytidine.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Cell Assay |
Initially plated at 2000 cells/cm2, cultures are measured using a Z2 Coulter Counter. After treating RG2 rat glioma cells once for 24 hours with 0, 1, 10, or 50 µM BrdU, cumulative growth curves were measured over a period of 18 days. After five, twelve, and eighteen days of treatment, control and treated cells are counted and replated at equal densities.
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C9H11BRN2O5
|
|
|---|---|---|
| Molecular Weight |
307.1
|
|
| Exact Mass |
305.99
|
|
| Elemental Analysis |
C, 35.20; H, 3.61; Br, 26.02; N, 9.12; O, 26.05
|
|
| CAS # |
59-14-3
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)Br)CO)O
|
|
| InChi Key |
WOVKYSAHUYNSMH-RRKCRQDMSA-N
|
|
| InChi Code |
InChI=1S/C9H11BrN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
|
|
| Chemical Name |
5-bromo-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 14.29 mg/mL (46.53 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2563 mL | 16.2813 mL | 32.5627 mL | |
| 5 mM | 0.6513 mL | 3.2563 mL | 6.5125 mL | |
| 10 mM | 0.3256 mL | 1.6281 mL | 3.2563 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00001650 | Completed | N/A | Acquired Immunodeficiency Syndrome HIV Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
May 13, 2011 | N/A |
| NCT00003832 | Completed | Procedure: conventional surgery Drug: bromodeoxyuridine |
Stage I Prostate Cancer Stage IIA Prostate Cancer |
National Cancer Institute (NCI) |
July 1999 | Phase 2 |
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
